Register for New Oral Anticoagulants

Conditions

Anticoagulation Treatment

Brief summary

Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register. Within this register a characterization of patients (with regard to demography and indication) and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.

Beyer-Westendorf J, Marten S, Naue C, Tittl L, Hänsel U, Beyer-Westendorf I, Mizera H, Schreier T, Festerling E, Reitter A, Spindler M, Bornhäuser M.

2020-04-191 citations

10.1016/j.thromres.2020.03.021

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study

Min Jun, Lisa M. Lix, Madéleine Durand, Matt Dahl, J. Michael Paterson et al. (13 authors)

BMJ2017-10-1792 citations

10.1136/bmj.j4323

Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.

Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dörschel S, Marten S.

2016-10-0143 citations

10.1016/s2352-3026(16)30111-9

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Jan Beyer‐Westendorf, Kati Förster, Sven Pannach, Franziska Ebertz, Vera Gelbricht et al. (13 authors)

Blood2014-05-24400 citations

10.1182/blood-2014-03-563577

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* indication for treatment with long term anticoagulation * initial adjustment or change to nex oral anticoagulant within routine treatment * indication for treatment with long term anticoagulation within the register: * permanent anticoagulation in arterial fibrillation * intended anticoagulation in acute venous thromboembolism for min. 3 months * other anticoagulation for min. 3 months within the approved indication

Exclusion criteria

* missing Informed Consent Form * missing phone number for telephone follow up * contraindication for therapy with new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) according to Summary of Product Characteristics

Countries

Germany

Contacts

Primary ContactJan Beyer-Westendorf, MD

jan.beyer@uniklinikum-dresden.de+49 351 458

Outcome results